This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 278453.
ClinicalTrials.gov Identifier:
NCT02035540
News
Early results of the ESPOIR Trial now published
The early results of the ESPOIR Trial and the ESPOIR Registry, including a matched comparison to conventional cryopreserved homografts and bovine jugular vein conduits (Contegra®) now have been published and are available here. [more]
Patient lecture and seminar on regenerative heart valves and stem cell therapy options - 30.03.2019 in the Hannover Zoo
Patientenseminar: Regenerative Therapien und Stammzelltherapie bei angeborenen Herzfehlern – geht das schon? [more]
EACTS 2018 in Milano - Initial results from the prospective ESPOIR Trial and ESPOIR Registry data presented on Thursday 18th of October 2018
Early data from the ESPOIR Trial was presented at the EACTS Annual Meeting in Milano on 18th of October in a Rapid Response Session. The abstract of the presentation can be found here on the site 6. [more]
Welcome to ESPOIR
Beginning in January 2012, the European Union will fund the European Clinical Study for the Application of Regenerative Heart Valves (ESPOIR) trial, coordinated by the Hannover Medical School, Germany, with a grant of 5.2 Million Euros for a period of four years. The aim of ESPOIR is to transplant a heart valve, which is tolerated by the patient’s immune system, lasts a lifetime and, for children, even holds the potential to grow with the patient.